Replies to post #713797 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

Agreed. Without large cash injection from big pharma or perhaps FDA BLA submission, it wont hold $1 post UK approval.

[dennisdave]

What would the pricing and reimubursement in the UK? undervalued at $7-$8? 7 x 1.7 = 11.9B and 8 x 1.7=13.6B. Pure and unadultered fantasy..... You really think they can do $2B in sales in UK alone without reibursement? Flaskworks is in pipedream carrot stage of development. Why would that hold any value?

There are 200,000 GBM patients worldwide each year. After UK approval MD's worldwide will start directing their patients to DCVAXL. With a patient's life depending on it Im sure at least 5% to 10% can afford DCVAXL treatment of let's say $150k. So let's assume 1000 patients of these 200,000 patients worldwide will, after UK approval, get DCVAXL treatment in 2025 x $150k = $150 million revenue x 10 multiplier makes a deserved 1.5 billion market cap for NWBO, which should take us above $1. However, the problem remains OTC.

[dstock07734]

Your theory doesn't suit.
Read more about science, think of DCVax-L as a platform, and investigate about what a platform can do.
Finishing this as your homework will benefit your tremendously.